Dr. Saab on a Phase II Study of the Oncolytic Virus Reolysin for Pancreatic Cancer

Tanios Bekaii-Saab, MD
Published: Tuesday, Sep 30, 2014

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.

The virus did not improve outcomes in the overall population of 73 patients in this study. Some patients may have benefited, Saab says, and researchers are still looking at blood and tissue samples for a potential biomarker. Interestingly, of the patients that crossed over, one patient responded and one had stable disease – this can most likely be attributed to the virus.

<<< View more from the 2014 ESMO Congress

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.

The virus did not improve outcomes in the overall population of 73 patients in this study. Some patients may have benefited, Saab says, and researchers are still looking at blood and tissue samples for a potential biomarker. Interestingly, of the patients that crossed over, one patient responded and one had stable disease – this can most likely be attributed to the virus.

<<< View more from the 2014 ESMO Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x